TLR7/8 Agonist，TLR7/8 agonist, such as R848 and VB6236, can activate the TLR7/8 signaling pathway, upregulate the type I inteferon, strength the antigen presentation by antigent presenting cells. This feature make it a promising drug candidate for the treatment of cancer and virus infection.
VB6893 is a TLR7/8 agonist prodrug, and can be metabolized into the more active form in tumor cells. This drug candidate is currently in preclinical phase and its IND application will be submitted by the end of 2024.
Peptide drug conjugation of TLR7/8 agonist and a tumor targeting peptide or other functional peptide for enhanced drug concentration/higher potency and less drug toxicity.